Scalp biopsy technique for the hair surgeon

Robert S. Haber, MD Cleveland, Ohio, USA HaberDerm@gmail.com

Hair transplant surgeons are often faced with diagnostic uncertainty with regard to hair loss etiology. Patients presenting for surgical options may have scalp conditions that preclude surgery, and it is incumbent upon the surgeon to be able to properly diagnose these conditions. In addition to a careful history and examination of the scalp and hair shaft, it is helpful and often necessary to obtain a biopsy to assess histopathologic changes. Hair transplant surgeons without a dermatology background are often unsure about proper biopsy technique, and sometimes there are no convenient or willing dermatologists to see these patients. Therefore, to properly and more fully be considered an expert in hair loss, all scalp surgeons should be comfortable obtaining these specimens. The purpose of this article is to summarize the scalp biopsy technique to maximize diagnostic accuracy. Only a small subset of scalp conditions will be discussed, since mastery of the basic technique will allow specimen collection of virtually any disease process. An accompanying instructional video will be available in the near future in the ISHRS online Members Only Video Library.

Scalp conditions that usually require biopsy include all forms of scarring alopecia such as the following:

- Chronic cutaneous lupus erythematosus
- Lichen planopilaris
- Frontal fibrosing alopecia
- Graham-Little syndrome
- Pseudopelade of Brocq
- Central centrifugal cicatricial alopecia
- Alopecia mucinosa
- Keratosis follicularis spinulosa decalvans
- Folliculitis decalvans
- Dissecting cellulitis/folliculitis

Scalp conditions that infrequently require biopsy consist of non-scarring alopecias including telogen effluvium and alopecia areata. Scalp conditions that only rarely benefit from biopsy include hormone-mediated male and female pattern hair loss. In any patient where there is diagnostic uncertainty and where therapeutic options will be altered by an accurate diagnosis, a biopsy should be performed. One example is what would appear to be a non-scarring alopecia in a patient with lupus or lichen planus or other condition known to cause scarring hair loss. Another example is suspected trichotillomania where alopecia areata is a likely alternative.

The most important step in a scalp biopsy is determining the correct biopsy location. Selecting a site without diagnostic histologic features is a waste of time. The ideal site should be neither burnt out nor intensely inflamed. Hair transplant surgeons without a dermatology background are often unsure about proper biopsy technique, and sometimes there are no convenient or willing dermatologists to see these patients. Therefore, to properly and more fully be considered an expert in hair loss, all scalp surgeons should be comfortable obtaining these specimens. The purpose of this article is to summarize the scalp biopsy technique to maximize diagnostic accuracy. Only a small subset of scalp conditions will be discussed, since mastery of the basic technique will allow specimen collection of virtually any disease process. An accompanying instructional video will be available in the near future in the ISHRS online Members Only Video Library.

Scalp conditions that usually require biopsy include all forms of scarring alopecia such as the following:

- Chronic cutaneous lupus erythematosus
- Lichen planopilaris
- Frontal fibrosing alopecia
- Graham-Little syndrome
- Pseudopelade of Brocq
- Central centrifugal cicatricial alopecia
- Alopecia mucinosa
- Keratosis follicularis spinulosa decalvans
- Folliculitis decalvans
- Dissecting cellulitis/folliculitis

Scalp conditions that infrequently require biopsy consist of non-scarring alopecias including telogen effluvium and alopecia areata. Scalp conditions that only rarely benefit from biopsy include hormone-mediated male and female pattern hair loss. In any patient where there is diagnostic uncertainty and where therapeutic options will be altered by an accurate diagnosis, a biopsy should be performed. One example is what would appear to be a non-scarring alopecia in a patient with lupus or lichen planus or other condition known to cause scarring hair loss. Another example is suspected trichotillomania where alopecia areata is a likely alternative.

The most important step in a scalp biopsy is determining the correct biopsy location. Selecting a site without diagnostic histologic features is a waste of time. The ideal site should be neither burnt out nor intensely inflamed. Captured tissue should include active inflammation if present and at least several hair follicles, and should generally be located at the periphery of an active area of hair loss.

Case 1

This 19-year-old girl presented to me with a diagnosis of discoid lupus on plaquenil therapy. She had presented to her primary care physician with new onset hair loss, and labs were obtained revealing an elevated ANA, triggering the diagnosis and treatment. My examination revealed a well-demarcated area of hair loss without evidence of scarring, but with inflammatory pustules (Figure 1).

Figure 1. Alopecic area showing inflammatory pustules.

Figure 2. Closeup showing selected biopsy site. Note exclamation mark hairs and absence of apparent scarring.
The multidisciplinary nature of our society is one of its most important assets. Looking at the same problem from the perspective of different specialties has allowed us to make rapid improvements in both our technologies and their results. It is these multiple viewpoints combined with the acceptance of aggressive, sometimes even harsh, critical communications, true intellectual presentation, and defense that drive our technological improvements.

This problem permeates all of medicine today, not just our specialty. Medical education in general has become so focused on “what they need to know to specialize,” that often younger physicians are not aware of the mistakes and successes that preceded their introduction to the specialty. I often hear, “I don’t need to learn scalp reduction or a Mangubat-Brandy Scalp Lift—they are procedures that have been abandoned or are of limited value.” And, yes, it may be true that you do not need to know how to do these procedures to be efficient with today’s routine HRS technology, but sooner or later you will see a patient who has had one of these done and is looking for the benefit of contemporary technology. If you do not know the anatomical changes, the impact of the flap on blood supply or wound healing, you may find that both you and your patient are in serious trouble when things do not work out as planned. Last summer I had a patient who had a large squamous cell carcinoma excised from his crown by a local Mohs surgeon who did not appreciate the changes in scalp tissue created by his prior two Juri Flaps. He was unable to close the wound, and left a 7cm×8cm defect open to heal by secondary intent.

The fact this problem may be getting worse. We know there are medical device companies marketing their HRS equipment by trivializing the physician’s role and responsibilities both in treatment planning and in performing the procedure. I feel the ISHRS must reach out to these new physicians and encourage them into proper training, lest sooner or later patients will be harmed, and our profession will carry the blemish for years to come.

We soon will congregate in San Francisco for our 21st annual meeting. My hope is that the new members will find experienced mentors, and the senior members will seek out the new members with whom to share their experience and encourage them to understand the value of becoming “fully trained” hair restoration surgeons. Bob Niedbalski and his Fellowship Training Committee are working to develop an online fellowship training program to help fill this void. Hopefully, it will be ready to launch in 2014.

As we prepare for the October San Francisco meeting, a few colleagues have noted along with me how many papers are offered that seem to reintroduce or reinvestigate ideas that were offered or discussed 25 or 30 years ago. I suppose this observation has been made at some time or another by everyone who has been professionally active for a quarter of a century. Of late, I have been thinking that as an educational society, we have a responsibility to try to minimize these redundancies and reinventions by providing new members with insights about what transpired in the years before they arrived.

Understand, I am not discouraging new eyes looking at old problems. I am suggesting that those minds may be more productive if they, and we, spent a little more time reviewing the details of what was done years ago. We know that we learn more from our mistakes than our successes, and sharing both facilitates the development of the specialty and serves our patients.

President’s Message

Carlos J. Puig, DO
Houston, Texas, USA

“Be to ignorant of what occurred before you were born is to remain always a child.”

—Marcus Tullius Cicero
Co-editors’ Messages
Nilofer P. Farjo, MBChB Manchester, United Kingdom editors@ISHRS.org

We have been having debates of late about the role of the assistant in FUE procedures. But what I think we need to be very clear about is that we need our assistants—it is impossible to do our surgeries without them. Back in the good old days when 300 grafts was a large operation, a doctor and an assistant were all that was needed, but now with strip harvesting a team of 10 or more is commonplace. Even with FUE, it is customary to have at least 4 assistants. Making your assistants part of the development of your practice is key to getting them engaged in patient care and the improvement of your technique. The aim is to instill in your technicians a sense of pride in what they are doing. A good way to do this is to ensure they view the post-operative results—either by seeing the patient when they return for a follow-up or by seeing the post-op photographs. Also, it’s important for assistants to see the problems that can arise, which can be done by including them in your morbidity and mortality case reviews.

Sometimes your team members may look at things from a different angle or come up with an idea that you hadn’t thought about. And sometimes it’s the little things that count. Let me give an example. For many years, we used Chinagraph pencils for marking up the recipient area before using a surgical marker so that the patient could have a look and we could make adjustments. These pencils became difficult to obtain and also their composition changed so they didn’t mark as well. So we then tried Kohl eyebrow pencils, but we couldn’t get them to draw well on the skin either. The oil from the patient’s skin made it difficult to mark up. After having bought several different makes, I was getting increasingly frustrated. Then one of our assistants said, “Just put the pencils in the fridge and they’ll draw okay.” And presto, problem solved.

One of the key things we did when we designed our new clinic was to engage the staff in its development. We looked at their needs, not just at those of the patient. So we made sure that the surgeries had easy to clean benching and flooring, good ventilation, ergonomic chairs, and excellent lighting, for example. Staff changing areas and lunch room needed to be of sufficient size and comfort so that staff could have their own areas to relax. Finally, we developed training rooms so that we could do either small group seminars or larger scale teaching. Ongoing training is a very important part of our staff development. Some of it is compulsory, but some is optional, and it is up to the individual team member to choose whether they move up the development path.

I was excited to read our president’s message in the last Forum and to learn that the ISHRS is taking steps to financially support well-designed research protocols by small groups of independent physicians. To me, it affirms that the ISHRS is dedicated to coordinating and educating individual physicians in the face of consolidation that seems to be occurring throughout the world of free markets and capitalism—from retail and Walmarts to health care and Hospital Corporation of America and United Healthcare Insurance Company.

I was also encouraged to learn of business models wherein group practices, such as DHI as Dr. Puig noted, are patient focused…at least for the time being. What concerns me is what happens to a business model as it matures and its founders fade away, and their ethics and high ideals are replaced by, well, business mind-sets. I have long felt that one of the historically consistent ideal relationships is that of the healer with his or her patient. As physicians, we have been given the opportunity and perhaps the responsibility to participate in realizing the high ideals of our profession for the benefit of our patients.

I have lived through a period in the United States when I have seen firsthand the doctor-patient relationship decimated by the business model and capitalism. The doctor-patient relationship has fallen victim to “efficiencies” whose impact has stolen the time and therefore the ability to relate to one’s patients in a manner that can preserve the healing nature of the physician’s art. The doctor’s relationship to the patient has become of secondary importance to business concerns, i.e., to maximizing profits.

My concern about group practices is that sooner or later with the progression of capitalism they are taken over by a publicly traded company where maximizing stockholders’ return on investment is of paramount importance. At some point, a hatchet man is brought in to be CEO to squeeze profits for the bottom line and for the shareholders’ dividends. We’ve seen this too many times to need further convincing that this is the progression of capitalism. Some have called it Social Darwinism. None of us would argue that an hour for a patient consultation is a wonderful option we have, but a luxury that can be trimmed by the Hatchet Man in the name of efficiency.

Not long ago I came across the Frankfurt School of Neo-Marxism. They were stuck on the question of how modern Europe at the peak of its sophistication and self-development could produce a fascism that was strong throughout Europe and produced such inhumane behaviors. Their conclusion was the Age of Enlightenment and its Reason produced men who, when in power, were capable of applying reason that was divorced from the rest of their non-rational selves including any empathy for others. He’s the Hatchet Man CEO. He is praised by his circle of capitalists who concur that his mission and the mission statement of the capitalist corporation is to maximize profits, period.

While the Neo-Marxists were in a bind observing that capitalism produced fascists, and Marxism, the Gulag, we physicians need not be so stuck. Our precious gem is the physician-patient relationship that is best preserved by a decentralized modus operandi: the individual physician supported by organizations such as the ISHRS that encourage dialogue, friendship, and education. Dr. Puig’s call for the individual to get involved in our Society and to participate and even take the role of leader is one that I was encouraged to learn about. Our organization is more than capable of taking steps to financially support well-designed research protocols by small groups of independent physicians. We have been given the opportunity and perhaps the responsibility to participate in realizing the high ideals of our profession for the benefit of our patients.

Co-editors’ Messages
Nilofer P. Farjo, MBChB Manchester, United Kingdom editors@ISHRS.org

Hair Transplant Forum International September/October 2013

www.ISHRS.org

Nilofer P. Farjo, MBChB Manchester, United Kingdom editors@ISHRS.org

The doctor’s relationship to the patient has become of secondary manner that can preserve the healing nature of the physician’s art. time and therefore the ability to relate to one’s patients in a that has fallen victim to “efficiencies” whose impact has stolen the ideals of our profession for the benefit of our patients. Perhaps the responsibility to participate in realizing the high consistent ideal relationships is that of the healer with his or her patients. As physicians, we have been given the opportunity and perhaps the responsibility to participate in realizing the high business mind-sets. I have long felt that one of the historically consistent ideal relationships is that of the healer with his or her patient. As physicians, we have been given the opportunity and perhaps the responsibility to participate in realizing the high ideals of our profession for the benefit of our patients.

One of the key things we did when we designed our new clinic was to engage the staff in its development. We looked at their needs, not just at those of the patient. So we made sure that the surgeries had easy to clean benching and flooring, good ventilation, ergonomic chairs, and excellent lighting, for example. Staff changing areas and lunch room needed to be of sufficient size and comfort so that staff could have their own areas to relax. Finally, we developed training rooms so that we could do either small group seminars or larger scale teaching. Ongoing training is a very important part of our staff development. Some of it is compulsory, but some is optional, and it is up to the individual team member to choose whether they move up the development path.

I was also encouraged to learn of business models wherein group practices, such as DHI as Dr. Puig noted, are patient focused…at least for the time being. What concerns me is what happens to a business model as it matures and its founders fade away, and their ethics and high ideals are replaced by, well, business mind-sets. I have long felt that one of the historically consistent ideal relationships is that of the healer with his or her patient. As physicians, we have been given the opportunity and perhaps the responsibility to participate in realizing the high ideals of our profession for the benefit of our patients.

I have lived through a period in the United States when I have seen firsthand the doctor-patient relationship decimated by the business model and capitalism. The doctor-patient relationship has fallen victim to “efficiencies” whose impact has stolen the time and therefore the ability to relate to one’s patients in a manner that can preserve the healing nature of the physician’s art. The doctor’s relationship to the patient has become of secondary importance to business concerns, i.e., to maximizing profits.
lead in refining our knowledge reflects what the ISHRS aspires to be as well as reminds us of our responsibilities as individual physicians. Be responsible or, ultimately, become employed by the Hatchet Man.

I remember talking to a technician from a group practice in years past who related the emergence within the group of a layer of middle management who monitored “time efficiencies,” including variables such as overtime, staffing excesses, and equipment usages. There’s nothing wrong with this as long as it doesn’t dehumanize the patient’s experience and relationship with the doctor and his or her staff. Such intangibles are not efficient, however, and, since such concerns involve the patient’s feelings, this empathy is not something the Hatchet Man knows to value. Comfortable staffing levels where the technician is rested and has time to engage the patient in conversation is inefficient from his perspective.

So close, the ISHRS is just what is needed by the individual physician. We physicians need to be conscious, however, that the forces of Social Darwinism are always present to co-opt the individualism currently constituting the ISHRS. The ISHRS, as Dr. Puig illustrates, is doing its part by bringing together physicians to accomplish tasks that only a group can do well, well-designed studies in his cited example. If we value our independence, we need to become engaged in the ISHRS to ensure its continuing independence. A Hatchet Man is always just outside the door salivating at the sweet smell of the inefficiencies that constitute Quality not only for our patients but for us and the way we practice medicine.

Reed Message

from page 159
Notes from the Editor Emeritus
Dow B. Stough, MD Hot Springs, Arkansas, USA db4@cablelynx.com

Say goodbye to post-op pain medications?

When I read the efficacy and safety data from clinical trials introducing a new single dose, non-opioid local anesthesia, I was excited. Bupivacaine liposome injectable suspension represents an old drug that has been reformulated with novel liposomal technology. The trade name for this drug is Exparel®, available through Pacira Pharmaceuticals. It is touted as the only single-dose analgesic that provides up to 72 hours of post-op analgesia; the technology used to reformulate bupivacaine is known as Depo Foam (the product delivery platform). This multivesicular liposomal technology can encapsulate a drug without altering its molecular structure. The drug is then released slowly over a desired period of time. The pharmacokinetic profile supplied by the company is impressive. It demonstrates plasma levels of bupivacaine persisting for up to 96 hours after administration. Keep in mind that any systemic levels of bupivacaine following the local administration cannot be correlated to local efficacy. It is important to remember that the rate of systemic absorption of any local anesthetic is dependent upon the route of administration, the method of administration, and the vascularity of the administration site. Local anesthetics for scalp use generally do not have the persistence in efficacy as elsewhere in the body. The scalp is vascular and local anesthesia may be carried off quickly with a resultant short-lived duration. I believe that there is a pressing need for a longer acting local anesthetic for our specialty.

Now back to Exparel. Could this new local anesthetic be the answer? We offer an elective procedure that can present challenges in the management of post-surgical pain. Even with the current FUE techniques, pain can be an issue. A physician has to be astute enough to separate the drug seekers from those with true post-op surgical pain. Then there are issues of dosing narcotics based on body weight, the route of administration, and the rare allergic reaction. It certainly has been my experience that most individuals allergic to “codeine-derived” products are simply describing an episode of severe nausea. Could all of these concerns simply vanish with a single, novel local anesthetic? No more prescriptions, no more nausea, no more calls. Now granted, I am glad to hear back from my patients on their status, but I don’t get particularly excited when they report nausea, post-op vomiting, or the ineffectiveness of my post-operative pain regimen. And yes, the issue of driving while under the influence of opioids must be addressed as well. A long-acting effective local anesthetic would negate all of these concerns.

In pivotal Phase II trials, Exparel was administered using a standard anal block procedure prior to hemorrhoidectomy. The perianal tissue was infiltrated in a fan-like fashion. One hundred and eighty-nine subjects participated in the trial; half were given placebo and the other half Exparel. While the results were quite impressive, my thoughts kept wandering to the unfortunate group of subjects who received placebo after a hemorrhoidectomy. Back to the Phase II trials, the findings showed almost a 50% decrease in opioid consumption. There was a significant increase in time to the first opioid use among subjects receiving Exparel. Most importantly, three times more Exparel patients were opioid free at 72 hours. The placebo group did not fare as well. Without going into a lot of detail, let’s just say this was an impressive study demonstrating the effectiveness of this long-acting liposomal bupivacaine. Bupivacaine is not without its concerns. While there was no QTC prolongation and no cardiac events in this study, these possibilities certainly linger in the back of my mind. The company points out there are no significant interactions of this with epinephrine, corticosteroids, antibiotics, or non-steroidal anti-inflammatory or oral opioids.

Armed with all the available information on this newly approved drug, I planned my course of action. I elected to use Exparel in every single patient that underwent transplantation in our clinic. Prior to the initial strip removal, Exparel was used in initial cases as the only local anesthetic. The drug cost is a factor at approximately $200 per surgery case, but probably well worth it if it becomes the panacea we are looking for. Exparel is supplied in a ready-to-use aggregate suspension or it can be diluted with normal saline to accommodate administration for a large area, such as the scalp. I elected to dilute it in a ratio of 50/50 with normal saline. I did not receive this suggested dilution from the sales representative or an article…I was just guessing here. This provided exactly 40ml of anesthesia from a 20ml vial. I also did not administer Exparel with a 25 gauge needle as recommended and instead opted for a 30 gauge needle. The Exparel was stored in a refrigerator prior to use and prior to dilution with saline. Once diluted, it was kept at room temperature for the remainder of the case. My initial impression was, “This stuff really hurts.” Nearly all of my patients tolerated this local anesthesia poorly. Well, would it make sense to use Lidocaine prior to administration of Exparel? You can’t! Non-bupivacaine-based local anesthesia, such as lidocaine, causes an immediate release of bupivacaine from Exparel. The injection of Exparel may follow the administration of lidocaine after a delay of 20 minutes or more. Some of my colleagues (not the makers of Exparel) have expressed concerns about the administration of bupivacaine after lidocaine since the receptor sites are already blocked at that time and the patient may not experience the long-acting effects of bupivacaine. At this point, something had to give. Patients simply could not tolerate Exparel at the beginning of the procedure.

After operating on a dozen or so patients, I decided to alter my protocol and administer Exparel at the end of the procedure; at least an hour after the last dose of lidocaine had been given. The result was more impressive. It still hurt, but less. Thus, I believe that when this novel local anesthetic is given at the conclusion of procedure, it does reduce the need for opioids, just as any commercially available Marcaine® or Naropin® would do. I have been performing administration of local anesthesia to the donor site at the end of procedures for my entire career and believe...
it is helpful. Is Exparel better than generic bupivacaine in the above setting? Maybe.

The unanswered question is, “How much longer is the pain relief patients actually experience?” I have no doubt this product is wonderful for hemorrhoidectomy patients and other post-operative surgical procedures. I’m just not convinced it is significantly better than the existing bupivacaine when used in the manner described above. It definitely works. It definitely hurts. To determine how much better will take years to sort out, new dilutional ratios, several thousand patients, and the input of ISHRS physicians.

This editorial was not meant in any way to be a review of Exparel. There are other issues you need to read about concerning this drug. Be careful in patients with hepatic disease, because it is metabolized by the liver. I do, however, encourage you to try Exparel as the potential is there. Google it on the Internet, contact the representative, ask about pricing, and give it a whirl.

The author has no past, present, or future consulting agreement with Pacira Pharmaceuticals, manufacturer of Exparel.
Scalp biopsy

from front page

There were also numerous exclamation mark hairs, a diagnostic feature of alopecia areata. The history and atypical presentation warranted a biopsy. A biopsy site was selected at the periphery of the alopecic area, and included a pustule (Figure 2). A 4mm punch biopsy was obtained, and the wound was closed with 4-0 Nylon. Histopathology revealed the findings of a non-inflammatory alopecia consistent with alopecia areata. No features of lupus were seen. Based on these findings, a diagnosis of alopecia areata was made, the plaquinil was discontinued, and intralesional injections of triamcinolone were initiated. If necessary, immunohistology specimens would have been obtained.

Case 2

This 31-year-old Caucasian man presented with a long history of inflammatory hair loss treated with intralesional injections of triamcinolone. Examination revealed extensive patchy inflammation and follicular pustulosis (Figure 3). Figure 4 shows an example of a poor choice for a biopsy site. The extensive inflammation present might obscure important diagnostic features. Figure 5 shows a better biopsy site. Histopathology revealed the diagnostic features of folliculitis decalvans.

Figure 3. Patchy inflammation and follicular pustulosis.

Figure 4. Potentially poor biopsy site due to extensive inflammation.

Figure 5. Chosen biopsy site with less pronounced inflammation.

Case 3

This 50-year-old Caucasian woman presented with a many year history of slowly progressive frontal hair loss. There was no history of skin disease elsewhere on her body. Examination revealed evidence of scarring and perifollicular erythema (Figure 6). A biopsy site was selected near the periphery of the alopecic area and it included several inflamed follicular orifices. Histology revealed the findings of lichen planopilaris (LPP).

Figure 6. Scarring and perifollicular erythema and selected biopsy site at periphery.

Case 4

This 48-year-old Caucasian woman presented with a long history of facial papular mucinosis (Figure 7), and the more recent onset of hair loss involving the scalp and eyebrows. Examination revealed perifollicular erythema and scarring changes (Figure 8). The history and findings produced a differential diagnosis of alopecia mucinosis and LPP, and warranted a biopsy. In this case, a biopsy site was selected from the center of the affected area due to a cluster of affected follicles (Figure 9). A 4mm punch biopsy was obtained, with special stains revealing no mucin deposition, and with routine histology revealing the findings of LPP.

The biopsy technique itself is fairly straightforward. Required equipment includes a 4mm punch biopsy, sharp dissection scissors, forceps, and materials to place one or two sutures (Figure 10). After administration of local anesthetic (Figure 11), hairs to be captured in the punch are trimmed (Figure 12). The punch is angled parallel to the hair shaft direction to minimize hair shaft transection (Figure 13), and gently rotated until the blade has fully penetrated the scalp (Figure 14). Expect a lot of bleeding at this point due to the generous vascularity of the scalp (Figure 15).
Scalp biopsy

from page 163

15). Using forceps, gently grasp and elevate the specimen (Figure 16). In some scalps, the specimen will separate easily from the underlying tissue without cutting. If necessary, using sharp dissection scissors, free the specimen from its deep dermal attachment. Close the wound with two interrupted 4-0 Nylon sutures or other closure of choice (Figure 17), and be prepared to hold pressure on this wound for a few additional minutes until bleeding has fully abated.

Most scalp conditions can be diagnosed with a single 4 mm punch specimen, which can be transected for processing in both vertical and horizontal orientations. At times, a second specimen may be required. Thus, working closely with your dermatopathologist is important to ensure that the desired specimens are submitted.

Mastering the punch biopsy technique is fairly trivial for a scalp surgeon, but it is crucial for proper patient care. Sending a patient to a dermatologist for a scalp biopsy can entail a delay of many months and the patient may incur significant expense. Handling this yourself will result in a speedier diagnosis and allow initiation of proper management more quickly.